Hørsholm, Denmark, April 03, 2024
As of August 2023, Dr. Claus Møller-San Pedro took over as the new CEO of Inphena ApS, now a part of AFYX Therapeutics A/S. During an Extraordinary General Meeting in December 2023 our Board of Directors (BOD) was expanded to 3 persons with a new Chairman of the Board – Dr. Ole Baadsgaard. In addition, Pia Cille Leah Laursen was elected to the BOD bringing significant international marketing and logistics experience to the company – both these Board Members were reelected to the BOD at annual general meeting today as well as Dr. Møller our CEO. In addition, a 4th member was elected to the BOD – Mr. Søren Kjær. Mr. Kjær brings with him more than 30 years of banking and financing experience.
Inphena A/S, Lionheart ApS and AFYX Therapeutics A/S has now been fully integrated to our new organization operating under the name AFYX Therapeutics A/S with a 100% owned daughter company – AFYX Development A/S – responsible for all our development activities and IP.
In 2023 we have product sales of DKK 35,5M. The result of the year shows that the group collectively ended with a loss of approximately DKK 2M after tax. The BOD believes that the company in its new shape and form is on track for continued growth and development and the Executive management and BOD are looking forward to driving the new entity created by the merger of the three organizations towards significant international success.
CLAUS J. MØLLER-SAN PEDRO
CEO & Founder
WE IMPROVE PEOPLE’S LIVES BY TRANSFORMING TOMORROW’S TREATMENTS
AFYX Therapeutics A/S – Our company is a niche biopharmaceutical company with focus on reformulation and repurposing of pharmaceuticals. Dr. Claus J. Møller-San Pedro is the company CEO. Dr. Møller co-founded and has secured successful IPOs of 3 other companies in the BioPharma Industry (OXiGENE Inc., Genmab A/S and Y-mAbs Therapeutics Inc)
Our focus is:
• OBSTETRICS
• NICHE ONCOLOGY
• PAIN AND ADDICTION
Contact: inquiry@afyxtx.com | +45 7174 7174